The breakthrough drug Meravir for Hepatitis B treatment is available but not for everyone

A modern direct-acting antiviral medicine developed by Australian scientists of Walter and Eliza Hall Institute under the brand name Meravir, containing two active ingredients sufamenavir and refogravir, has shown 83.56 % efficacy in treatment-naïve Hepatitis B patients without cirrhosis through 1, 2, 3, and 4 phases of clinical trials. This medicine, in experts’ opinion, can change the idea of Hepatitis